DexCom, Inc. (NASDAQ:DXCM) Receives $140.94 Average Target Price from Brokerages

DexCom, Inc. (NASDAQ:DXCM) has been given an average rating of “Moderate Buy” by the fifteen research firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $140.33.

Several analysts have issued reports on the company. Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. UBS Group lifted their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James raised their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Finally, Redburn Atlantic assumed coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock.

DexCom Trading Up 2.9 %

NASDAQ DXCM opened at $113.51 on Friday. The stock has a market capitalization of $45.14 billion, a price-to-earnings ratio of 73.23, a PEG ratio of 2.69 and a beta of 1.22. The business’s fifty day moving average is $124.29 and its 200-day moving average is $125.85. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. Equities research analysts predict that DexCom will post 1.78 EPS for the current year.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now directly owns 283,893 shares in the company, valued at approximately $39,262,401.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,076 shares of company stock worth $7,544,030. Corporate insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Cary Street Partners Investment Advisory LLC grew its holdings in shares of DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after purchasing an additional 115 shares during the last quarter. CX Institutional bought a new position in shares of DexCom during the fourth quarter valued at about $286,000. abrdn plc boosted its holdings in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after purchasing an additional 66,348 shares during the period. Bank of New Hampshire bought a new stake in shares of DexCom in the first quarter worth about $1,508,000. Finally, Cerity Partners LLC increased its holdings in DexCom by 5,791.0% during the 4th quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock valued at $57,574,000 after purchasing an additional 456,097 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.